Skip to main content
  • Tweet
  • Share on Facebook
  • Share on Google +1
  • Share via Email
  • Contact
  • Glossary
  • Subscribe
  • Search

PATH's Malaria Vaccine Initiative

Accelerating Malaria Vaccine Development

  • Malaria, vaccines & biologics
    • Need for vaccines
      • Malaria vaccine roadmap
      • Preferred product characteristics
    • Malaria parasite life cycle
  • R&D and Introduction
    • First-generation vaccines
    • Next-generation vaccines
      • Pre-erythrocytic vaccine candidates
      • Blood-stage vaccine candidates
      • Transmission-blocking vaccine candidates
      • Combination vaccine candidates
    • Monoclonal antibodies
  • RTS,S
    • Piloting RTS,S
      • Cost of delivering RTS,S
      • Public health impact and cost-effectiveness
      • Qualitative study on vaccine use
      • Case control studies
    • Clinical trial history of RTS,S
      • RTS,S use in seasonal settings
    • Expanded use of RTS,S
  • Access
    • Preparing for malaria vaccine decisions
      • Global policy and regulatory pathways
      • Decision-making framework
        • The decision-making framework for malaria vaccines
        • Economic analysis
        • Public health impact analysis
        • Sociocultural research
    • Financing
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Publications
    • Videos
    • Reports
    • Past projects
  • News
    • Press releases
    • Perspectives
  • About us
    • Donors
    • Contact us
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Tools for advocates
    • Propose a project
  • Malaria, vaccines & biologics
    • Need for vaccines
      • Malaria vaccine roadmap
      • Preferred product characteristics
    • Malaria parasite life cycle
  • R&D and Introduction
    • First-generation vaccines
    • Next-generation vaccines
      • Pre-erythrocytic vaccine candidates
      • Blood-stage vaccine candidates
      • Transmission-blocking vaccine candidates
      • Combination vaccine candidates
    • Monoclonal antibodies
  • RTS,S
    • Piloting RTS,S
      • Cost of delivering RTS,S
      • Public health impact and cost-effectiveness
      • Qualitative study on vaccine use
      • Case control studies
    • Clinical trial history of RTS,S
      • RTS,S use in seasonal settings
    • Expanded use of RTS,S
  • Access
    • Preparing for malaria vaccine decisions
      • Global policy and regulatory pathways
      • Decision-making framework
    • Financing
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Publications
    • Videos
    • Reports
    • Past projects
  • News
    • Press releases
    • Perspectives
  • About us
    • Donors
    • Contact us
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Tools for advocates
    • Propose a project
  • Home
  • Home

Phased expansion of malaria vaccine use begins in more areas in Africa

Kenya joins Ghana and Malawi in rolling out the vaccine to more children at risk

PATH applauds WHO recommendation for broader use of first malaria vaccine in sub-Saharan Africa

Vaccine shown to be cost-effective and trusted by caregivers and health care workers

PATH welcomes WHO prequalification of the first malaria vaccine

The vaccine's prequalification is a key step in protecting children and reducing the burden of malaria.

PATH welcomes commitment by Gavi board to finance wider rollout of the world’s first malaria vaccine, RTS,S

Together with partners and other stakeholders, PATH is working to help ensure sufficient malaria vaccine supply to meet potential demand.

Home

  • Malaria parasite life cycle

    Many factors make malaria vaccine development challenging.
    Explore
  • R&D and Introduction

    MVI's strategy supports the near-term goal of controlling malaria in the populations most at risk, as well as the long-term goal of complete eradication of the disease.
    Explore
  • RTS,S/AS01

    The first vaccine recommended for use by the World Health Organization to prevent malaria in children.
    Explore

Latest

Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program
Journal article
17 Mar 2023
RTS,S/AS01 Malaria Vaccine Technical Brief
Report
14 Mar 2023
Nurse Lucy Igunza Muhonja vaccinates baby Aden in Kenya's Vihiga County. Photo credit: PATH Phased expansion of malaria vaccine use begins in more areas in Africa
Press release
7 Mar 2023
PATH welcomes WHO prequalification of the first malaria vaccine
Press release
6 Sep 2022
RTS,S/AS01 malaria vaccine being drawn up by a healthcare worker in western Kenya. PATH welcomes US$ 5 million grant to expand malaria vaccine access in Ghana, Kenya, and Malawi
Press release
19 Apr 2022
PATH welcomes commitment by Gavi board to finance wider rollout of the world’s first malaria vaccine, RTS,S
Press release
2 Dec 2021
PATH applauds WHO recommendation for broader use of first malaria vaccine
Press release
6 Oct 2021
Frequently Asked Questions (FAQs): RTS,S/AS01 for seasonal use
Fact sheet
25 Aug 2021
PATH welcomes remarkable results from clinical trial combining RTS,S/AS01 malaria vaccine with Seasonal Malaria Chemoprevention
Press release
25 Aug 2021
PATH welcomes landmark financing agreement for GSK’s malaria vaccine
Press release
4 Aug 2021
GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine
Press release
27 Jan 2021
Frequently Asked Questions (FAQs): Product Transfer for the RTS,S/AS01 Malaria Vaccine
Fact sheet
27 Jan 2021
  • Need for vaccines

    Vaccines can help to close the gap left by other malaria control interventions.
  • Malaria vaccine roadmap

    The roadmap outlines a path for accelerating the development of malaria vaccines.
  • RTS,S/AS01

    The first vaccine recommended for use by the World Health Organization to prevent malaria in...
  • Next-generation vaccines

    The next generation of malaria vaccines would aim to increase efficacy, durability or protection...

Twitter @MalariaVaccine

The expansion of RTS,S malaria vaccine use to more areas of Ghana, Kenya, and Malawi through 2023 is made possible by funding from @open_phil, using vaccine doses donated by @GSK, the manufacturer, & in collaboration with @WHO and country partners. Thank you to all our partners! https://t.co/MnXkEVp8Bz
9 Mar 2023
RT @PATHMalaria: Whether its @RuthWanjala strengthening #vaccine communications in #Kenya or Dr. Sampa Pal's work on G6PD tests, wom… https://t.co/mqrgTiBAWk
8 Mar 2023
RT @amsroy: Great thread if you want to find out more about the expansion of the world's first #MalariaVaccine in Kenya! Congratulations @MOH_Kenya @VaccinesKenya @PATHtweets @WHOKenya and all other partners on reaching this significant milestone! https://t.co/lx1s4euLhL
7 Mar 2023
Starting today, the world’s first malaria vaccine, RTS,S, will become available to more children in Kenya’s lake endemic region, following similar expansions in Ghana and Malawi. Congratulations @VaccinesKenya @MOH_Kenya and all partners on reaching this important milestone! https://t.co/9ZYdEES9AX
7 Mar 2023
RT @RuthWanjala: A great milestone of this work as the vaccine is scaled up in Kenya with support from @WHOKenya @PATHtweets @UNICEFKenya @DNMPKenya and @VaccinesKenya @MalariaVaccine #malariavaccine https://t.co/P6Tn6addA6
7 Mar 2023
"At @PATHtweets, we are proud to have contributed throughout the journey to develop, evaluate and implement a proven and life-saving malaria vaccine,” said Dr Scott Gordon in Nairobi today as Kenya prepares to expand use of the RTS,S malaria vaccine to more children. https://t.co/P3uemI8UaU
6 Mar 2023
RT @WHOGhana: Ghana🇬🇭 is making efforts to eliminate malaria. The country with support from @WHO, @PATHtweets, @UNICEF, @gavi & other partners has launched an expansion of the malaria immunization program to deliver malaria vaccines to more children. Read more: https://t.co/CyX7XBSqht https://t.co/qY2thEdhgp
21 Feb 2023
Yesterday marked another important milestone for world’s first #MalariaVaccine, RTS,S, as Ministry of Health made this added tool against malaria available to more children in Ghana. Great to see PATH’s John Bawa join MOH officials, WHO, community leaders, others, at this event! https://t.co/KkjUmarihv
21 Feb 2023
RT @wellcometrust: The first malaria vaccine has reached more than a million children in Ghana, Kenya and Malawi so far, significantly… https://t.co/SEFvuiWLgJ
2 Feb 2023
RT @WHO: @DrTedros @GlobalGoalsUN @UN @UNEP "Meanwhile, the 🌍’s first #malaria vaccine, RTS,S, is saving lives. In 🇬🇭, 🇰🇪 &… https://t.co/A8Q8drysX6
30 Jan 2023
RT @Fredros_Inc: What if the RTS,S Malaria vaccine is seasonally-targeted? ~ Thompson et al: Seasonally targeting RTS,S may yield gr… https://t.co/jLXpHIKDmW
27 Jan 2023
RT @dsw_intl: We’re looking forward to hearing from @PeterHotez and @PCuresResearch at the launch of the upcoming #GFINDER… https://t.co/GM6uw38ioC
26 Jan 2023

PATH Washington DC

455 Massachusetts Avenue NW, Suite 1000

Washington, DC 20001 | USA 

Tel: 202.822.0033

Fax: 202.457.1466

Email: mvi_info [at] path.org

PATH Headquarters

2201 Westlake Avenue, Suite 200

Seattle, WA 98121 | USA 

Tel: 206.285.3500

Fax: 206.285.6619

Email: info [at] path.org

Website: www.path.org

Follow us

Mail
Twitter
  • Privacy policy
  • Copyright policy
  • Terms of use
© 2023 PATH
Website by Manta Ray Media